
India is gearing up to launch Inclisiran, a cholesterol-lowering vaccine designed to significantly decrease LDL-C and reduce heart attack/stroke risks. Priced at Rs 1.2 lakhs per dose, affordability concerns arise despite the biannual dosage requirement. A study reveals 213 million Indians suffer from dyslipidemia. Novartis India has secured import and marketing approval for Inclisiran. The vaccine, coupled with dietary changes, targets mixed dyslipidemia, necessitating a 284mg dose every six months. Inclisiran, compatible with statins, functions as a gene-silencing medication, enhancing the liver's cholesterol removal.
Like
Save
Share